Interferons are proteins made by the human immune
system for fighting viral infections and regulating
cell function. Three types of interferons are used as drugs: interferon alpha, interferon
beta, and interferon gamma. They are used by injection to treat viral infections, hepatitis, multiple
sclerosis, some cancers, and other diseases.
The information in this article pertains to interferon in general. The interactions
reported here may not apply to all the Also Indexed As terms. Talk to your doctor or
pharmacist if you are taking any of these drugs.
Interactions with Dietary Supplements
N-acetyl cysteine
(NAC)
One preliminary trial found that adding 600 mg NAC three times per day to interferon therapy
for people with chronic hepatitis C led to improvement
in their conditions not seen with interferon alone.1 However, other
preliminary2 3 and double-blind trials4 5 have
failed to confirm the efficacy of this approach. At the present time, sufficient evidence is
lacking to support the use of this drug-nutrient combination in persons with hepatitis.
Thymus
peptides
Peptides or short proteins derived from the immune organ known as the thymus gland have been
investigated in combination with interferon therapy for people with hepatitis B and C. One
study found that adding thymus humoral factor-gamma 2 to interferon therapy prevented
decreases in white blood cell counts sometimes seen with interferon alone, and also seemed to
improve the efficacy of interferon against hepatitis B.6 Thymus humoral
factor-gamma 2 must be administered by injection, requiring consultation with a doctor. It is
not known whether orally administered thymus extracts would be useful in combination with
interferon.
References:
1. Beloqui O, Prieto J, Sua’rez B, et al. N-Acetyl cysteine
enhances the response to interferon-alpha in chronic hepatitis C: A pilot study. J
Interferon Res 1993;13:279–82.
2. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination
therapy for chronic hepatitis C--a controlled pilot trial. Antiviral Res
1999;43:113–22.
3. Cimino L, Belisario MA, Intrieri M, et al. Effect of N-acetyl-cysteine
on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic
hepatitis. Ital J Gastroenterol Hepatol 1998;30:189–93.
4. Grant PR, Black A, Garcia N, et al. Combination therapy with
interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled
double-blind multicentre study. J Med Virol 2000;61:439–42.
5. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined
with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a
randomized, multicentre study. Eur J Gastroenterol Hepatol 1999;11:1203–7.
6. Farhat BA, Marinos G, Daniels HM, et al. Evaluation of efficacy and
safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J
Hepatol 1995;23:21–7.
7. Nakagawa A, Yamaguchi I, Takao T, Amano H. Five cases of drug-induced
pneumonitis due to sho-saiko-to or interferon alpha or both. Nippon Kyobu Shikkan Gakkai
Zasshi 1995;33:1361–6 [in Japanese].
8. Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon
and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J
1996;9:2691–6.
9. Sugiyama H, Nagai M, Kotajima F, et al. A case of interstitial
pneumonia with chronic hepatitis C following interferon-alpha and sho-saiko-to therapy.
Arerugi 1995;44:711–4 [in Japanese].
10. Sato A, Toyoshima M, Kondo A, et al. Pneumonitis induced by the
herbal medicine Sho-saiko-to in Japan. Nippon Kyobu Shikkan Gakkai Zasshi
1997;35:391–5 [in Japanese].
11. Fujisawa K. Interferon therapy in hepatitis C virus (HCV) induced
chronic hepatitis: Clinical significance of pretreatment with glycyrhizine. Trop
Gastroenterol 1991;12:176–9.
12. Abe Y, Ueda T, Kato T, et al. Effectiveness of interferon,
glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho
1994;52:1817–22 [in Japanese].
Copyright © 2002 Healthnotes, Inc. All rights
reserved. www.healthnotes.com
Please read the disclaimer
about the limitations of the information provided here. Do NOT rely solely on the information
in this article.
Learn more about Healthnotes, the company.
Learn more about the authors of
Safetychecker.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.